Braeburn Publishes Post Hoc Analysis of Phase 3 Study Data on BRIXADI
25 Jun 2024 //
PR NEWSWIRE
FDA Accepts Braeburn`s NDA Resubmission for BRIXADI Subcutaneous Injection
08 Dec 2022 //
PRNEWSWIRE
FDA Accepts Braeburn`s New Drug Application Resubmission for BRIXADi
26 Jun 2021 //
PR NEWSWIRE
Braeburn Resubmits New Drug Application for BRIXADI
15 Jun 2021 //
PRNEWSWIRE